Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
Top Cited Papers
- 8 June 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 74 (23), 1868-1876
- https://doi.org/10.1212/wnl.0b013e3181e24136
Abstract
Objective: To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). Methods: The percent brain volume change (PBVC) was computed on existing longitudinal (2 time points) T1-weighted MRI from untreated (trial and nontrial) patients with MS. Patients (n = 963) were classified as clinically isolated syndromes suggestive of MS (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%), and primary progressive (9%) MS. The median length of follow-up was 14 months (range 12–68). Results: There was marked heterogeneity of the annualized PBVC (PBVC/y) across MS subtypes (p = 0.003), with higher PBVC/y in SP than in CIS (p = 0.003). However, this heterogeneity disappeared when data were corrected for the baseline normalized brain volume. When the MS population was divided into trial and nontrial subjects, the heterogeneity of PBVC/y across MS subtypes was present only in the second group, due to the higher PBVC/y values found in trial data in CIS (p = 0.01) and RR (p < 0.001). The estimation of the sample sizes required for demonstrating a reduction of brain atrophy in patients in a placebo-controlled trial showed that this was larger in patients with early MS than in those with the progressive forms of the disease. Conclusions: This first large study in untreated patients with multiple sclerosis (MS) with different disease subtypes shows that brain atrophy proceeds relentlessly throughout the course of MS, with a rate that seems largely independent of the MS subtype, when adjusting for baseline brain volume.This publication has 39 references indexed in Scilit:
- Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosisNeurology, 2009
- Predicting short-term disability progression in early multiple sclerosis: added value of MRI parametersJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisNeurology, 2008
- Enhanced brain extraction improves the accuracy of brain atrophy estimationNeuroImage, 2008
- Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trialMultiple Sclerosis Journal, 2007
- Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registration‐Based MethodsJournal of Neuroimaging, 2007
- Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled studyThe Lancet Neurology, 2006
- Central Nervous System Atrophy and Clinical Status in Multiple SclerosisJournal of Neuroimaging, 2004
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983